Libo Pharma Corp

About Libo Pharma Founded in 2017, Libo Pharma Corp. is dedicated to developing innovative therapies that address significant unmet medical needs. Our lead asset, NM-IL-12, is a first-in-class cytokine-based immunomodulator with multiple mechanisms of action, including immune regulation, hematopoiesis enhancement, radiation damage mitigation, and anti-tumor activity. Our Lead Product: NM-IL-12 NM-IL-12 has received orphan drug designation from both the U.S. FDA and European Medicines Agency (EMA) for the treatment of cutaneous T-cell lymphoma (CTCL) and is advancing into a Phase 3 clinical trial, with strong potential for regulatory approval and commercialization. The product has also completed Phase 2 clinical trials for Hematopoietic Syndrome of Acute Radiation Syndrome(HSARS) and open wound healing, and is currently expanded into new indications including diffuse large B-cell lymphoma (DLBCL) and other solid tumors—highlighting a robust and diversified pipeline. Innovation & Capabilities Libo Pharma maintains a globally competitive intellectual property portfolio, covering key markets such as the United States, Europe, and Japan. We retain full control over the manufacturing processes and biological materials related to NM-IL-12, ensuring a high level of autonomy across product development and production. Backed by a highly experienced scientific and regulatory team, we are well-positioned to drive forward our development programs from clinical validation to commercial launch. Clinical Experience To date, NM-IL-12 has been administered in over 200 human subjects, consistently demonstrating a favorable safety and efficacy profile. Its ability to be used in combination with standard therapies including chemotherapy, radiotherapy, and immune checkpoint inhibitors offers promising opportunities to enhance treatment outcomes across multiple cancer types.